{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Masse moléculaire : Questions médicales les plus fréquentes",
"headline": "Masse moléculaire : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Masse moléculaire : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-08",
"dateModified": "2025-05-03",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Masse moléculaire"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Phénomènes chimiques",
"url": "https://questionsmedicales.fr/mesh/D055598",
"about": {
"@type": "MedicalCondition",
"name": "Phénomènes chimiques",
"code": {
"@type": "MedicalCode",
"code": "D055598",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G02"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Masse moléculaire",
"alternateName": "Molecular Weight",
"code": {
"@type": "MedicalCode",
"code": "D008970",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Dave J Adams",
"url": "https://questionsmedicales.fr/author/Dave%20J%20Adams",
"affiliation": {
"@type": "Organization",
"name": "School of Chemistry, University of Glasgow, Glasgow G12 8QQ, United Kingdom."
}
},
{
"@type": "Person",
"name": "Taro Yasumoto",
"url": "https://questionsmedicales.fr/author/Taro%20Yasumoto",
"affiliation": {
"@type": "Organization",
"name": "Division of Neurology, Department of Internal Medicine, School of Medicine, Showa University, Tokyo, Japan."
}
},
{
"@type": "Person",
"name": "Mayumi Tsuji",
"url": "https://questionsmedicales.fr/author/Mayumi%20Tsuji",
"affiliation": {
"@type": "Organization",
"name": "Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan."
}
},
{
"@type": "Person",
"name": "Shiro Nakamura",
"url": "https://questionsmedicales.fr/author/Shiro%20Nakamura",
"affiliation": {
"@type": "Organization",
"name": "Department of Oral Physiology, School of Dentistry, Showa University, Tokyo, Japan."
}
},
{
"@type": "Person",
"name": "Tomio Inoue",
"url": "https://questionsmedicales.fr/author/Tomio%20Inoue",
"affiliation": {
"@type": "Organization",
"name": "Department of Oral Physiology, School of Dentistry, Showa University, Tokyo, Japan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Overview of Physical, Neurocognitive, and Psychosocial Outcomes in Pediatric Intestinal Failure and Transplantation.",
"datePublished": "2022-08-30",
"url": "https://questionsmedicales.fr/article/36040624",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11894-022-00848-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "Characteristics of chronic intestinal failure in the USA based on analysis of claims data.",
"datePublished": "2022-07-24",
"url": "https://questionsmedicales.fr/article/35726729",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/jpen.2426"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effects of resistance training on sarcopenia in patients with intestinal failure: A randomized controlled trial.",
"datePublished": "2023-07-16",
"url": "https://questionsmedicales.fr/article/37625319",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.clnu.2023.07.013"
}
},
{
"@type": "ScholarlyArticle",
"name": "Efficacy of same venous route Hickman catheter replacement in patients with intestinal failure.",
"datePublished": "2022-10-28",
"url": "https://questionsmedicales.fr/article/37096641",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jfma.2022.10.003"
}
},
{
"@type": "ScholarlyArticle",
"name": "Body Composition and Physical Activity in Pediatric Intestinal Failure On and Off Parenteral Nutrition.",
"datePublished": "2023-07-12",
"url": "https://questionsmedicales.fr/article/37434279",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/MPG.0000000000003884"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes chimiques",
"item": "https://questionsmedicales.fr/mesh/D055598"
},
{
"@type": "ListItem",
"position": 3,
"name": "Masse moléculaire",
"item": "https://questionsmedicales.fr/mesh/D008970"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Masse moléculaire - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Masse moléculaire",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-05",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Masse moléculaire",
"description": "Comment mesure-t-on la masse moléculaire ?\nQuels instruments sont utilisés pour déterminer la masse moléculaire ?\nLa masse moléculaire est-elle importante en biologie ?\nPeut-on calculer la masse moléculaire d'une protéine ?\nQu'est-ce qu'une masse moléculaire moyenne ?",
"url": "https://questionsmedicales.fr/mesh/D008970?mesh_terms=Intestinal+Failure&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Masse moléculaire",
"description": "Quels symptômes peuvent indiquer une anomalie de masse moléculaire ?\nLa masse moléculaire affecte-t-elle la solubilité ?\nComment la masse moléculaire influence-t-elle l'absorption des médicaments ?\nY a-t-il des symptômes liés à des protéines de masse moléculaire élevée ?\nLes symptômes d'intolérance alimentaire sont-ils liés à la masse moléculaire ?",
"url": "https://questionsmedicales.fr/mesh/D008970?mesh_terms=Intestinal+Failure&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Masse moléculaire",
"description": "Comment prévenir les allergies liées à la masse moléculaire ?\nY a-t-il des mesures préventives pour les troubles métaboliques ?\nLa recherche sur la masse moléculaire peut-elle prévenir des maladies ?\nComment l'éducation nutritionnelle aide-t-elle à prévenir des problèmes liés à la masse moléculaire ?\nLes tests génétiques peuvent-ils prévenir des maladies liées à la masse moléculaire ?",
"url": "https://questionsmedicales.fr/mesh/D008970?mesh_terms=Intestinal+Failure&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Masse moléculaire",
"description": "Comment traiter une allergie liée à une masse moléculaire ?\nLes médicaments à masse moléculaire élevée sont-ils efficaces ?\nPeut-on modifier la masse moléculaire d'un médicament ?\nQuels traitements sont disponibles pour les troubles métaboliques ?\nComment les thérapies géniques sont-elles liées à la masse moléculaire ?",
"url": "https://questionsmedicales.fr/mesh/D008970?mesh_terms=Intestinal+Failure&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Masse moléculaire",
"description": "Quelles complications peuvent survenir avec des protéines de masse moléculaire élevée ?\nLes complications liées à la masse moléculaire affectent-elles le traitement ?\nComment les complications métaboliques sont-elles liées à la masse moléculaire ?\nLes complications allergiques peuvent-elles être graves ?\nQuelles sont les complications des médicaments à masse moléculaire élevée ?",
"url": "https://questionsmedicales.fr/mesh/D008970?mesh_terms=Intestinal+Failure&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Masse moléculaire",
"description": "Quels facteurs augmentent le risque d'allergies liées à la masse moléculaire ?\nLa génétique joue-t-elle un rôle dans les troubles liés à la masse moléculaire ?\nL'environnement influence-t-il la masse moléculaire des allergènes ?\nLe mode de vie peut-il affecter la masse moléculaire des substances ?\nQuels sont les facteurs de risque pour les maladies liées à la masse moléculaire ?",
"url": "https://questionsmedicales.fr/mesh/D008970?mesh_terms=Intestinal+Failure&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment mesure-t-on la masse moléculaire ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "La masse moléculaire est mesurée par des techniques comme la spectrométrie de masse."
}
},
{
"@type": "Question",
"name": "Quels instruments sont utilisés pour déterminer la masse moléculaire ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des appareils comme le chromatographe et le spectromètre de masse sont utilisés."
}
},
{
"@type": "Question",
"name": "La masse moléculaire est-elle importante en biologie ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle aide à comprendre les interactions moléculaires et les réactions biochimiques."
}
},
{
"@type": "Question",
"name": "Peut-on calculer la masse moléculaire d'une protéine ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, en additionnant les masses atomiques des acides aminés qui la composent."
}
},
{
"@type": "Question",
"name": "Qu'est-ce qu'une masse moléculaire moyenne ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "C'est la masse moléculaire calculée pour un mélange de molécules de différentes tailles."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer une anomalie de masse moléculaire ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des réactions allergiques ou des troubles métaboliques peuvent survenir."
}
},
{
"@type": "Question",
"name": "La masse moléculaire affecte-t-elle la solubilité ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une masse moléculaire élevée peut réduire la solubilité d'une substance dans l'eau."
}
},
{
"@type": "Question",
"name": "Comment la masse moléculaire influence-t-elle l'absorption des médicaments ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les médicaments à masse moléculaire faible sont généralement mieux absorbés par l'organisme."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes liés à des protéines de masse moléculaire élevée ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent causer des maladies comme l'amylose ou des troubles de la coagulation."
}
},
{
"@type": "Question",
"name": "Les symptômes d'intolérance alimentaire sont-ils liés à la masse moléculaire ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines intolérances peuvent être dues à des protéines de masse moléculaire élevée."
}
},
{
"@type": "Question",
"name": "Comment prévenir les allergies liées à la masse moléculaire ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évitez les allergènes connus et consultez un allergologue pour des tests appropriés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives pour les troubles métaboliques ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sain et une alimentation équilibrée peuvent aider à prévenir ces troubles."
}
},
{
"@type": "Question",
"name": "La recherche sur la masse moléculaire peut-elle prévenir des maladies ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut aider à identifier des biomarqueurs et des cibles thérapeutiques."
}
},
{
"@type": "Question",
"name": "Comment l'éducation nutritionnelle aide-t-elle à prévenir des problèmes liés à la masse moléculaire ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle informe sur les aliments à éviter et ceux à privilégier pour une bonne santé."
}
},
{
"@type": "Question",
"name": "Les tests génétiques peuvent-ils prévenir des maladies liées à la masse moléculaire ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent identifier des prédispositions à certaines maladies héréditaires."
}
},
{
"@type": "Question",
"name": "Comment traiter une allergie liée à une masse moléculaire ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut des antihistaminiques et l'évitement de l'allergène identifié."
}
},
{
"@type": "Question",
"name": "Les médicaments à masse moléculaire élevée sont-ils efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent être efficaces, mais leur absorption et leur distribution peuvent être limitées."
}
},
{
"@type": "Question",
"name": "Peut-on modifier la masse moléculaire d'un médicament ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, par des modifications chimiques pour améliorer l'efficacité ou la biodisponibilité."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les troubles métaboliques ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements incluent des régimes alimentaires spécifiques et des médicaments adaptés."
}
},
{
"@type": "Question",
"name": "Comment les thérapies géniques sont-elles liées à la masse moléculaire ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles utilisent des vecteurs de masse moléculaire spécifique pour délivrer des gènes thérapeutiques."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des protéines de masse moléculaire élevée ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent entraîner des maladies comme l'amylose ou des troubles de la coagulation."
}
},
{
"@type": "Question",
"name": "Les complications liées à la masse moléculaire affectent-elles le traitement ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent compliquer l'absorption et l'efficacité des traitements médicamenteux."
}
},
{
"@type": "Question",
"name": "Comment les complications métaboliques sont-elles liées à la masse moléculaire ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies dans la masse moléculaire des métabolites peuvent causer des dysfonctionnements."
}
},
{
"@type": "Question",
"name": "Les complications allergiques peuvent-elles être graves ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent entraîner des réactions anaphylactiques potentiellement mortelles."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications des médicaments à masse moléculaire élevée ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles incluent des effets secondaires, une biodisponibilité réduite et des interactions médicamenteuses."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'allergies liées à la masse moléculaire ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents familiaux d'allergies et une exposition précoce à des allergènes augmentent le risque."
}
},
{
"@type": "Question",
"name": "La génétique joue-t-elle un rôle dans les troubles liés à la masse moléculaire ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies métaboliques ont une composante génétique significative."
}
},
{
"@type": "Question",
"name": "L'environnement influence-t-il la masse moléculaire des allergènes ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des facteurs environnementaux comme la pollution peuvent modifier les allergènes."
}
},
{
"@type": "Question",
"name": "Le mode de vie peut-il affecter la masse moléculaire des substances ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation déséquilibrée peut influencer la composition et la masse moléculaire."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les maladies liées à la masse moléculaire ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'obésité, le diabète et des antécédents familiaux de maladies."
}
}
]
}
]
}
Intestinal failure and transplantation may significantly impact physical, neurocognitive, and psychosocial development in pediatric patients. Currently, there is a paucity of literature on the effects...
Psychological disorders, neurodevelopmental delay, and social maladaptation are frequently encountered in this patient population. While the main focus is often on medical management, equal emphasis s...
This study investigated the prevalence, characteristics, and management of patients with chronic intestinal failure (CIF) in the United States in 2012-2020, based on parenteral support (PS) prescripti...
Patients with CIF were identified from the Integrated DataVerse® claims database if they had at least two PS prescriptions within 6 months and a relevant diagnosis. Analysis included prevalence and ch...
Up to 24,048 patients with CIF were identified, equivalent to 75 patients per million. CIF affected people of all ages, being more prevalent in women than in men. Many providers signed PS orders for s...
Healthcare disparities for patients with CIF have likely been obscured by the lack of CIF-specific diagnostic and procedure codes, obliging providers to code for their patients under other codes. Effe...
The potential effects of resistance training on sarcopenia in patients with intestinal failure (IF) are not fully elucidated. This study aimed to explore the efficacy of a resistance training program ...
A single-center randomized controlled trial was conducted in a Chinese tertiary teaching hospital. Patients with IF exhibiting sarcopenia were randomly assigned to the exercise group or control group....
A total of 60 participants (control group 30, age 51.2 ± 12.9 years, women 43.3%; exercise group 30, age 53.9 ± 14.5 years, women 56.7%) completed the 4-week intervention trial. For the primary outcom...
In this randomized clinical trial, we observed that 4 weeks of resistance training was associated with improved ASMI, physical performance, biochemical parameters (including IGF-1, prealbumin, and hem...
www.chictr.org.cn, identifier: ChiCTR2100051727....
Periodical replacement of venous Hickman catheters is required for the nutritional care of patients with intestinal failure. The conventional de novo operation (DN-OP) involves inserting the catheter ...
We conducted a retrospective study to compare the efficacy of Hickman catheters and the survival of venous vessels using two different operative strategies....
Overall, 181 catheters were inserted, 109 using DN-OP and 72 using SR-OP. The mean catheter duration was 11.9 ± 8.8 months in the DN-OP group and 10.5 ± 5.6 months in the SR-OP group; the infection ra...
Application of SR-OP in Hickman catheter replacement significantly extended the working duration of venous access by re-using the same venous route without compromising catheter efficacy in patients w...
Data on the relationship between body composition (BC) and physical activity (PA) in children with intestinal failure (IF) are lacking. The objectives were to collect data on PA and BC in children wit...
Cross-sectional study in children 5-18 years with IF including those receiving parenteral nutrition (PN) and those fully enterally fed. PA levels were measured using accelerometry. BC was measured by ...
Fifty-eight children with IF (38 males), mean (SD) age of 10.0 (3.5) years, 20 dependent on PN were included. Patients with IF had significantly fewer steps per day ( P ≤ 0.001) compared with literatu...
Children with IF, those receiving PN and those fully enterally fed, are at risk of decreased PA and altered BC. PA should be part of ongoing rehabilitation and management to optimize outcomes....
There is a subset of intestinal failure patients with associated chronic intestinal inflammation resembling inflammatory bowel disease. This study aimed to evaluate factors associated with chronic int...
This was a single-center retrospective case-control study of children <18 years old with intestinal failure. Cases were defined by abnormal amounts of chronic intestinal inflammation on biopsies. Chil...
Thirty cases were identified and matched to 60 controls. On univariate analysis, longer parenteral nutrition (PN) duration (1677 vs 834 days, P = 0.03), current PN use (33.3% vs 20.0%, P = 0.037), and...
PN dependence and intestinal dysbiosis are associated with chronic intestinal inflammation in children with intestinal failure. Severity of inflammation is associated with escalation of therapy. Furth...
Intestinal dysmotility (ID) problems are common in patients with pediatric-onset intestinal failure (IF) and short bowel syndrome (SBS), leading to significant morbidity and delays in the advancement ...
Retrospective chart review of all children with IF and/or SBS who required parenteral nutrition (PN) > 6 weeks or small-intestinal resection ≥ 50%. Patients were divided into SBS and non-SBS groups. S...
A total of 42 children with IF were treated in our institution during 2003-2022. In non-SBS group (n = 10), ID was the most common cause of IF (80%). SBS-group included 32 children; 18 children (56%) ...
ID is the most common complication of SBS and is the most common cause of IF in non-SBS patients. ID has a high morbidity rate and various clinical manifestations. Successful treatment of these infant...
With increasing number of children with intestinal failure (IF) on long-term parenteral nutrition (PN), this study assesses the impact of IF on muscle strength, speed, and agility and body composition...
Cross-sectional study in children 5-18 years with IF on PN. Assessments included Bruininks-Oseretsky Test of Motor Proficiency-2 strength and agility subtest (BOT-2), and grip strength. BC data from d...
Twenty-one children with IF (14 males), median age 8.33 (IQR: 6.96-11.04) years and 33 controls (20 males), 8.25 (6.67-10.79) years were included. Strength and agility ( P < 0.001) and grip strengt...
Children with IF are at risk of decreased muscle strength and agility, along with altered BC. Ongoing medical, nutritional, and rehabilitation intervention is vital to optimize outcomes....
Patients with intestinal failure (IF) are often dependent on PN for provision of calories and nutrients for survival. Similar to chronic intestinal failure (CIF) patients, those who have AIF are also ...
The primary objective of this study was to determine the incidence of IFALD in AIF patients on short-term PN. Secondary objectives were to analyse patient and PN risk factors of IFALD, and clinical ou...
This was a retrospective cross-sectional cohort study of hospitalised adult patients with AIF prescribed with short-term PN. All adult patients aged 21 years and above who received PN for at least 5 c...
A total of 171 patients were enrolled in this study, with 77 (45%) having deranged LFTs at the end of PN therapy and categorised under the IFLAD group. The patient cohort was predominantly male (92 [5...
In this study, IFALD is a common phenomenon in AIF and the incidence was found to be an estimated 50% amongst patients on short-term PN with similar clinical outcomes between the two groups....
This post-hoc analysis evaluated the effect of teduglutide treatment on diarrhea in patients with short bowel syndrome-associated intestinal failure (SBS-IF)....
Data from 2 open-label, multicenter, phase 3 pediatric SBS-IF clinical trials of teduglutide (NCT01952080 and NCT02682381) were pooled where possible. The primary objective was to evaluate the change ...
Overall, 101 patients were analyzed. Among the total teduglutide group (n = 87), there were significant changes from baseline to weeks 12 and 24 in mean (standard error) Bristol Stool Form Scale (BSFS...
In this post-hoc analysis, short-term treatment with teduglutide was associated with improved stool consistency, as well as trends towards reductions in PN/IV requirements and advancements in enteral ...